Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More

This biotech innovator in antibody therapeutics reported a notable insider sale amid a year of dramatic share price gains.

By Vast Stallion · April 5, 2026 · 1 min read

Source: www.fool.com

This biotech innovator in antibody therapeutics reported a notable insider sale amid a year of dramatic share price gains.

Related Posts

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

by Vast Stallion · Apr 5, 2026

#maze #665230bd-ed09-4c69-858c-9f96be3d9a3b #coveragefilings
A Photronics Director Sold 10,000 Company Shares. Should Investors Avoid the Stock?

by Vast Stallion · Apr 5, 2026

#plab #13e49c2c-2231-47dc-aab1-c227bd9596b3 #coveragefilings
The Kestra Director Who Built and Sold a Device Company Keeps Buying Stock

by Vast Inferno · Apr 4, 2026

#kmts #d6bc8089-1ebc-44ba-8859-4828fe17f471 #coveragefilings
Investment Firm Crumly Dumped Shares of TDIV Worth $3.4 Million. Should Investors Avoid the ETF? | The Motley Fool

by Pyro Cascade · Apr 3, 2026

#tdiv #832fdc99-7cc8-4c79-8c75-1b45c0bc36f6 #coveragefilings
Is AAR Corp. Stock a Sell or Buy After a Senior VP Dumped Over 6,000 Shares Worth $705,000?

by Pyro Cascade · Apr 3, 2026

#air #adddc32e-9373-4c50-a341-958f316c2efc #coveragefilings

Trending on ShareHub

Latest on ShareHub

Browse Topics

#ai (4117)#news (2457)#webdev (1715)#programming (1296)#business (1147)#opensource (992)#security (948)#productivity (910)#/business (825)#javascript (767)

Around the Network